A less sour sweet; blocking galectin

Helen Heslop

doi:10.1182/blood-2011-03-337683

A less sour sweet; blocking galectin

Helen Heslop

Research output: Contribution to journal › Comment/debate › peer-review

1 Scopus citations

Abstract

In this issue of Blood,Ouyang et al describe both an important tumor immune evasion strategy and ameans by which it can be overcome.1 They show that EBV proteins LMP1 and 2A induce expression of galectin-1 (Gal1) by the B lymphoblasts of EBV⁺ posttransplantation lymphoproliferative disease (PTLD), and that they could block the apoptosis this sugar-binding molecule would otherwise induce in effector cytotoxicTlymphocytes using aGal1 directed monoclonal antibody.

Original language	English (US)
Pages (from-to)	4165-4166
Number of pages	2
Journal	Blood
Volume	117
Issue number	16
DOIs	https://doi.org/10.1182/blood-2011-03-337683
State	Published - Apr 21 2011

ASJC Scopus subject areas

Biochemistry
Immunology
Hematology
Cell Biology

Access to Document

10.1182/blood-2011-03-337683

Cite this

@article{27ee1bee1d85489b9701392180004587,

title = "A less sour sweet; blocking galectin",

abstract = "In this issue of Blood,Ouyang et al describe both an important tumor immune evasion strategy and ameans by which it can be overcome.1 They show that EBV proteins LMP1 and 2A induce expression of galectin-1 (Gal1) by the B lymphoblasts of EBV+ posttransplantation lymphoproliferative disease (PTLD), and that they could block the apoptosis this sugar-binding molecule would otherwise induce in effector cytotoxicTlymphocytes using aGal1 directed monoclonal antibody.",

author = "Helen Heslop",

year = "2011",

month = apr,

day = "21",

doi = "10.1182/blood-2011-03-337683",

language = "English (US)",

volume = "117",

pages = "4165--4166",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "16",

}

TY - JOUR

T1 - A less sour sweet; blocking galectin

AU - Heslop, Helen

PY - 2011/4/21

Y1 - 2011/4/21

N2 - In this issue of Blood,Ouyang et al describe both an important tumor immune evasion strategy and ameans by which it can be overcome.1 They show that EBV proteins LMP1 and 2A induce expression of galectin-1 (Gal1) by the B lymphoblasts of EBV+ posttransplantation lymphoproliferative disease (PTLD), and that they could block the apoptosis this sugar-binding molecule would otherwise induce in effector cytotoxicTlymphocytes using aGal1 directed monoclonal antibody.

AB - In this issue of Blood,Ouyang et al describe both an important tumor immune evasion strategy and ameans by which it can be overcome.1 They show that EBV proteins LMP1 and 2A induce expression of galectin-1 (Gal1) by the B lymphoblasts of EBV+ posttransplantation lymphoproliferative disease (PTLD), and that they could block the apoptosis this sugar-binding molecule would otherwise induce in effector cytotoxicTlymphocytes using aGal1 directed monoclonal antibody.

UR - http://www.scopus.com/inward/record.url?scp=79955968997&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955968997&partnerID=8YFLogxK

U2 - 10.1182/blood-2011-03-337683

DO - 10.1182/blood-2011-03-337683

M3 - Comment/debate

C2 - 21511962

AN - SCOPUS:79955968997

SN - 0006-4971

VL - 117

SP - 4165

EP - 4166

JO - Blood

JF - Blood

IS - 16

ER -

A less sour sweet; blocking galectin

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this